Potassium-sparing renal effects of trimethoprim and structural analogues.
OBJECTIVE
The antibiotic antagonists of folic acid trimethoprim, tetroxoprim, pyrimethamine and their antineoplastic analogue methotrexate have structural characteristics in common with the potassium-sparing diuretic triamterene. They may, therefore, share with triamterne potassium-sparing renal effects.


METHODS
Clearance studies were performed on anesthetized male Sprague-Dawley rats, and the drug effects on glomerular filtration rate and on urinary excretion of sodium, chloride, and potassium were studied.


RESULTS
Trimethoprim and tetroxoprim, injected intravenously at doses ranging from 0.3 to 30 mg/kg, induced dose-dependent natriuretic and antikaliuretic renal effects, whereas pyrimethamine at doses ranging from 1 to 10 mg/kg and methotrexate at doses ranging from 10 to 50 mg/kg did not affect urinary sodium and potassium excretion. An antikaliuretic effect was also observed after application of the structurally related antiprotozoal compound pentamidine at doses ranging from 3 to 10 mg/kg. In contrast to trimethoprim and tetroxoprim, the antikaliuresis was accompanied by a marked decrease of urinary sodium and chloride excretion at all of the doses tested. At 10 mg/kg, pentamidine induced a pronounced fall of the glomerular filtration rate (by 43.5%).


CONCLUSIONS
Trimethoprim and tetroxoprim share with potassium-sparing diuretics natriuretic and antikaliuretic renal effects which may be caused by similar mechanisms in the distal nephron, whereas pyrimthamine and methotrexate do not. A depression of renal hemodynamics is an important factor involved in the antikaliuretic effect of pentamidine.
Gabriëls
G
G
Department of Pharmacology and Toxicology, Rheinisch-Westfälische Technische Hochschule, Aachen, Germany. gabrie@uni-muenster.de
Stockem
E
E
Greven
J
J
D000818:Animals; D000890:Anti-Infective Agents / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D002712:Chlorides / Q000652:urine; D004305:Dose-Response Relationship, Drug; D005493:Folic Acid Antagonists / Q000494:pharmacology*; D005919:Glomerular Filtration Rate; D007668:Kidney / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D008727:Methotrexate / Q000494:pharmacology; D011188:Potassium / Q000378:metabolism*; D011739:Pyrimethamine / Q000494:pharmacology; D011743:Pyrimidines / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D012964:Sodium / Q000652:urine; D013997:Time Factors; D014295:Trimethoprim / Q000031:analogs & derivatives* / Q000494:pharmacology*
D000890:Anti-Infective Agents; D002712:Chlorides; D005493:Folic Acid Antagonists; D011743:Pyrimidines; C023507:tetroxoprim; D012964:Sodium; D014295:Trimethoprim; D011188:Potassium; D008727:Methotrexate; D011739:Pyrimethamine